Alzheimer therapy clinical stage drugmaker hires IP expert to be GC and COO
Neurotrope Inc., a clinical-stage biopharmaceutical company that’s developing therapies for such neurodegenerative diseases as Alzheimer’s disease, hired Michael Ciraolo as general counsel and chief operating officer.
Ciraolo was most recently at Ovid Therapeutics, where he was senior vice president, chief intellectual property counsel. Before that, he was an executive director at Forest Laboratories. He has been involved with the development of various pharmaceutical products and transactional matters, including mergers, acquisitions and licensing opportunities. Ciraolo began his legal career as an associate at Baker Botts in New York, received a Ph.D. in chemistry from Stony Brook University and a J.D. from St. John’s University School of Law.
“I am very pleased to welcome Michael to the Neurotrope executive management team,” said Charles Ryan, Neurotrope’s chief executive officer. “He is an exceptional leader and lawyer and we expect will prove instrumental as we continue to execute at this important point in the Company’s evolution. We look forward to reporting top-line data from our current Phase 2 confirmatory clinical trial in the second half of 2019, and to making continued progress in exploring Bryostatin’s potential in other disease indications.”